INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARENEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (
NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, March 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or “the Company”) (
NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
CLASS ACTION INVESTOR ALERTS: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ultragenyx and Mereo BioPharma and Encourages Investors to Contact the FirmNEW YORK, March 08, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ultragenyx Pharmaceutical Inc. (
NASDAQ:RARE) and Mereo BioPharma Group plc (
NASDAQ:MREO). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Ultragenyx Pharmaceutical Inc. (RARE) Investors Have Opportunity to Lead Securities Fraud Class Action LawsuitSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, March 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or “the Company”) (
NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action Lawsuit Filed; April 6, 2026, Lead Plaintiff DeadlineSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARENEW ORLEANS, March 04, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE), if they purchased or otherwise acquired the Company’s shares between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, DeadlineSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action – April 6, 2026 Lead Plaintiff Deadline - Furuqi & Furuqi LLPUltragenyx Pharmaceuticals Investors With Significant Losses Are Encouraged To Contact Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson To Discuss Their Legal Rights
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineNEW YORK and NEW ORLEANS, March 03, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE) of a class action securities lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARENEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (
NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, March 03, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or “the Company”) (
NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 DeadlinePHILADELPHIA, March 02, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (
NASDAQ: RARE) (“Ultragenyx” or the “Company”) on behalf of investors who purchased common shares of Ultragenyx during the period from August 3, 2023 through December 26, 2025 (the “Class Period”).
RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors With Losses to Contact the FirmSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors With Losses to Contact the FirmSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARENEW ORLEANS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE), if they purchased or otherwise acquired the Company’s shares between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
